Morepen Laboratories (NSE:MOREPENLAB) Selling, General, & Admin. Expense: ₹990 Mil (TTM As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
75 GF Score
Price ₹61.22
GF Value ₹49.93
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Morepen Laboratories Selling, General, & Admin. Expense?

Morepen Laboratories NSE:MOREPENLAB +0.43% 75 Selling, General, & Admin. Expense is ₹990 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹49.93 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Morepen Laboratories's selling, general, & admin. expense for the three months ended in Mar. 2026 was ₹349 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹990 Mil.


Morepen Laboratories  (NSE:MOREPENLAB) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Morepen Laboratories Selling, General, & Admin. Expense Related Terms


Morepen Laboratories Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Selling, General, & Admin. Expense Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 677.65 1,071.76 1,273.15 799.86 989.76

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.86 303.96 138.64 198.08 349.08

NSE:MOREPENLAB vs ZTS, UTHR: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Selling, General, & Admin. Expense falls into.


NSE:MOREPENLAB
75GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹990 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of ₹990 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Selling, General, & Admin. Expense of ₹990 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Selling, General, & Admin. Expense too high?
Morepen Laboratories' current Selling, General, & Admin. Expense is ₹990 Mil. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Selling, General, & Admin. Expense compare to ZTS and UTHR?
Morepen Laboratories' Selling, General, & Admin. Expense of ₹990 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Selling, General, & Admin. Expense is ₹990 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.93, compared to a current price of ₹61.22 — trading 22.6% above its estimated fair value. The current Selling, General, & Admin. Expense is ₹990 Mil. Morepen Laboratories' overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Selling, General, & Admin. Expense is ₹990 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹61.22 is trading 22.6% above its estimated GF Value™ of ₹49.93. GuruFocus considers Morepen Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Selling, General, & Admin. Expense: ₹990 Mil
  • GF Value™: ₹49.93 vs. price of ₹61.22 (22.6% above fair value)
  • GF Score™: 75/100 with 9 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score

Get the complete analysis for NSE:MOREPENLAB

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹61.22
Price
₹49.93
GF Value